The estimated Net Worth of Murray Stewart is at least $368 mil dollars as of 9 August 2023. Mr. Stewart owns over 130,056 units of X4 Pharmaceuticals stock worth over $101,088 and over the last 7 years he sold XFOR stock worth over $137,859. In addition, he makes $129,052 as Independent Director at X4 Pharmaceuticals.
Murray has made over 1 trades of the X4 Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 130,056 units of XFOR stock worth $137,859 on 9 August 2023.
The largest trade he's ever made was selling 130,056 units of X4 Pharmaceuticals stock on 9 August 2023 worth over $137,859. On average, Murray trades about 8,670 units every 0 days since 2017. As of 9 August 2023 he still owns at least 146,504 units of X4 Pharmaceuticals stock.
You can see the complete history of Mr. Stewart stock trades at the bottom of the page.
Murray W. Stewart M.D. serves as Independent Director of the Company. Mr. Wyzga served as Chairman of the X4 board of directors since July 2018. Mr. Wyzga is currently the President of MSW Consulting Inc., a strategic consulting group focused in the life sciences area. From December 2011 until November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc., a publicly traded biopharmaceutical company. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, a publicly traded global biotechnology company. Mr. Wyzga joined Genzyme in February 1998 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as chief financial officer from July 1999 until November 2011. From February 2014 to December 2018, Mr. Wyzga served as a member of the board of directors of Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was also a member of the compensation committee and chair of the audit committee. Since February 2015, Mr. Wyzga has also served as a member of the board of directors of Exact Sciences Corporation, a publicly traded medical technology company, where he is also a member of the audit and compensation committees. From October 2013 until Oncomed Pharmaceuticals, Inc.’s business combination with Mereo BioPharma Group plc in April 2019, Mr. Wyzga served as a member of the board of directors of Oncomed Pharmaceuticals, Inc., where he was also a member of the audit committee. Since February 2016, Mr. Wyzga has also served as Chairman of the board of directors of GenSight Biologics S.A., a Euronext traded biopharmaceutical company. Mr. Wyzga also previously served as a member of the board of directors of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Merck in August 2014, where he also served as the chair of the audit committee and a member of the compensation committee, and as a member of the
As the Independent Director of X4 Pharmaceuticals, the total compensation of Murray Stewart at X4 Pharmaceuticals is $129,052. There are 7 executives at X4 Pharmaceuticals getting paid more, with Paula Ragan having the highest compensation of $2,497,790.
Murray Stewart is 59, he's been the Independent Director of X4 Pharmaceuticals since 2019. There are 4 older and 9 younger executives at X4 Pharmaceuticals. The oldest executive at X4 Pharmaceuticals, Inc. is Dr. Robert David Arbeit, 73, who is the Sr. VP of Clinical Devel. and Translational Research.
Murray's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134.
Over the last 6 years, insiders at X4 Pharmaceuticals have traded over $2,179,690 worth of X4 Pharmaceuticals stock and bought 25,000 units worth $30,000 . The most active insiders traders include Paula Ragan, Adam S. Mostafa y Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of $12,232. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth $1,744.
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
X4 Pharmaceuticals executives and other stock owners filed with the SEC include: